14 DAY TRIAL // Scientists have developed a successful strategy for interfering with Ebola virus infection that protected 75 percent of nonhuman primates exposed to the lethal disease.
This is the first successful antiviral intervention against filoviruses like Ebola in nonhuman primates.
The findings could serve as the basis for a new approach to quickly develop virus-specific therapies for known, emerging, and genetically engineered pathogens.
In today's online issue of the journal Public Library of Science Pathogens, a research team led by Sina Bavari and colleagues at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) reports using novel "antisense" drugs to interrupt normal Ebola virus replication. The work was performed in collaboration with AVI BioPharma, a U.S. biotechnology firm.
According to the study's authors, antisense drugs are useful against viral diseases because they are designed to enter cells and eliminate viruses by preventing their replication. The drugs, which act by blocking critical viral genetic sequences, may be more potent than anti-virals such as protease inhibitors, which seek to inhibit a protein needed for viral replication.
Ebola virus causes hemorrhagic fever with case fatality rates as high as 80 percent in humans. The virus, which is infectious by aerosol (although more commonly spread through blood and bodily fluids of infected patients), is of concern both as a global health threat and a potential agent of biological warfare or terrorism. Currently there are no available vaccines or therapies.
"One advantage of this strategy is that it directly targets the virus. With Ebola infection, the virus grows so fast that it overtakes the host immune system. What we did, essentially, was to hold off the viral replication long enough for the host to mount an immune response and clear the virus," said the paper's first author, Kelly L. Warfield.